Drug recall D-0468-2023
Product
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Reason for recall
Labeling: Label Mix-up
Lots and codes
Lot #: a) and b) E61835, exp. date JUN 2025
Recall details
- Recalling firm
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
- Quantity
- 69,375 bottles
- Distribution
- Product was distributed nationwide within the United States and PR
- Type
- Voluntary: Firm initiated
- Recall initiated
- March 9, 2023
- Terminated
- December 4, 2023
Related products
- Jardiance – drug information
- NDC 0597-0152 Jardiance · Empagliflozin 10 mg/1 · Boehringer Ingelheim Pharmaceuticals, Inc.
- NDC 0597-0153 Jardiance · Empagliflozin 25 mg/1 · Boehringer Ingelheim Pharmaceuticals, Inc.